 |
 |

Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Byron E. Wright, MD;
Randall P. Scheri, MD;
Xing Ye, MS;
Mark B. Faries, MD;
Roderick R. Turner, MD;
Richard Essner, MD;
Donald L. Morton, MD
Arch Surg. 2008;143(9):892-900.
Hypothesis The status of the sentinel node (SN) confers important prognostic information for patients with thin melanoma.
Design, Setting, and Patients We queried our melanoma database to identify patients undergoing sentinel lymph node biopsy for thin ( 1.00-mm) cutaneous melanoma at a tertiary care cancer institute. Slides of tumor-positive SNs were reviewed by a melanoma pathologist to confirm nodal status and intranodal tumor burden, defined as isolated tumor cells, micrometastasis, or macrometastasis ( 0.20, 0.21-2.00, or >2.00 mm, respectively). Nodal status was correlated with patient age and primary tumor depth ( 0.25, 0.26-0.50, 0.51-0.75, or 0.76-1.00 mm). Survival was determined by log-rank test.
Main Outcome Measures Disease-free and melanoma-specific survival.
Results Of 1592 patients who underwent sentinel lymph node biopsy from 1991 to 2004, 631 (40%) had thin melanomas; 31 of the 631 patients (5%) had a tumor-positive SN. At a median follow-up of 57 months for the 631 patients, the mean (SD) 10-year rate of disease-free survival was 96% (1%) vs 54% (10%) for patients with tumor-negative vs tumor-positive SNs, respectively (P < .001); the mean (SD) 10-year rate of melanoma-specific survival was 98% (1%) vs 83% (8%), respectively (P < .001). Tumor-positive SNs were more common in patients aged 50 years and younger (P = .04). The SN status maintained importance on multivariate analysis for both disease-free survival (P < .001) and melanoma-specific survival (P < .001).
Conclusions The status of the SN is significantly linked to survival in patients with thin melanoma. Therefore, sentinel lymph node biopsy should be considered to obtain complete prognostic information.
Author Affiliations: Departments of Surgical Oncology (Drs Wright, Scheri, Faries, Essner, and Morton), Biostatistics (Ms Ye), and Pathology (Dr Turner), John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California.
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
False-Negative Sentinel Lymph Node Biopsy in Head and Neck Melanoma
Miller et al.
Otolaryngol Head Neck Surg 2011;145:606-611.
ABSTRACT
| FULL TEXT
Predictors of Occult Nodal Metastasis in Patients With Thin Melanoma
Faries et al.
Arch Surg 2010;145:137-142.
ABSTRACT
| FULL TEXT
Melanoma
Coit et al.
J Natl Compr Canc Netw 2009;7:250-275.
ABSTRACT
Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma
Andtbacka and Gershenwald
J Natl Compr Canc Netw 2009;7:308-317.
ABSTRACT
|